Korean Circulation Journal最新文献_第8页

Disparities in Heart Transplantation Allocation and Outcomes by Blood Type in Korea (2010-2022). 韩国心脏移植分配和结果的血型差异（2010-2022）。

IF 3 3区医学

Korean Circulation Journal Pub Date : 2025-06-01 Epub Date: 2025-03-28 DOI: 10.4070/kcj.2024.0281

Kyung-Hee Kim, Byoung Geol Choi, Jin-Oh Choi, In-Cheol Kim, Jong-Chan Youn, Yang Hyun Cho, Hae-Young Lee, Sung-Ho Jung, Byung-Hee Oh

{"title":"Disparities in Heart Transplantation Allocation and Outcomes by Blood Type in Korea (2010-2022).","authors":"Kyung-Hee Kim, Byoung Geol Choi, Jin-Oh Choi, In-Cheol Kim, Jong-Chan Youn, Yang Hyun Cho, Hae-Young Lee, Sung-Ho Jung, Byung-Hee Oh","doi":"10.4070/kcj.2024.0281","DOIUrl":"10.4070/kcj.2024.0281","url":null,"abstract":"Background and objectives: This study aimed to elucidate the influence of recipient blood type on heart transplant allocation dynamics in Korea, focusing on donor matching, wait times, and post-transplant survival from 2010 to 2022.Methods: In this retrospective cohort study, we examined 1,745 heart transplant recipients classified by blood types: A (n=631), B (n=488), AB (n=256), and O (n=370). Parameters studied encompassed donor and recipient ages, donor blood type compatibility, organ type, emergency status, waiting periods, and survival rates up to one year post-transplant.Results: This investigation revealed significant disparities in the outcomes for heart transplant waitlist patients, differentiated by blood type. O recipients encountered notably extended median wait times of 110 days (an average of 300±514 days), which is substantially longer compared to A (65 days), B (58 days), and AB (29 days). Furthermore, the mortality rate for O recipients while on the waitlist was markedly high at 78.1%, in contrast to 75.2% for A, 72.3% for B, and 48.5% for AB. O recipients who, despite constituting a significant proportion of the donor pool (34.1%), received transplants at disproportionately lower rates.Conclusions: Type O heart transplant recipients in Korea face significant challenges, including higher mortality rates during the waiting period and frequent necessity for left ventricular assist device interventions. Urgent policy reforms are needed to address these disparities and improve equitable organ allocation for blood type O patients.","PeriodicalId":17850,"journal":{"name":"Korean Circulation Journal","volume":" ","pages":"481-493"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12206615/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143989326","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advancing Solutions for Coronary Ostial Lesions. 冠状动脉口病变的先进解决方案。

IF 3 3区医学

Korean Circulation Journal Pub Date : 2025-06-01 Epub Date: 2025-04-01 DOI: 10.4070/kcj.2025.0097

Seokhun Yang, Kyung Woo Park

引用次数: 0

Safety and Performance of the Micra VR Leadless Pacemaker in a South Korean Cohort: A Comparison to Global Studies. Micra VR无铅起搏器在韩国队列中的安全性和性能：与全球研究的比较

IF 3 3区医学

Korean Circulation Journal Pub Date : 2025-06-01 Epub Date: 2025-02-13 DOI: 10.4070/kcj.2024.0317

Myung-Jin Cha, Seung-Jung Park, Youngjin Cho, Min Soo Cho, Young Keun On, Ju Youn Kim, Tae-Hoon Kim, Hee Tae Yu, Yong-Seog Oh, So-Ryoung Lee, Jaemin Shim, Jong-Il Choi, Eue-Keun Choi, Jongmin Hwang, Kurt Stromberg, Jeffrey Murphy, Dedra H Fagan, Boyoung Joung

{"title":"Safety and Performance of the Micra VR Leadless Pacemaker in a South Korean Cohort: A Comparison to Global Studies.","authors":"Myung-Jin Cha, Seung-Jung Park, Youngjin Cho, Min Soo Cho, Young Keun On, Ju Youn Kim, Tae-Hoon Kim, Hee Tae Yu, Yong-Seog Oh, So-Ryoung Lee, Jaemin Shim, Jong-Il Choi, Eue-Keun Choi, Jongmin Hwang, Kurt Stromberg, Jeffrey Murphy, Dedra H Fagan, Boyoung Joung","doi":"10.4070/kcj.2024.0317","DOIUrl":"10.4070/kcj.2024.0317","url":null,"abstract":"Background and objectives: The Micra leadless pacemaker demonstrated a favorable safety and efficacy profile in global trials, but its performance and safety in a South Korean-specific population are unknown.Methods: The prospective, single-arm Micra Acute Performance South Korean registry was designed to study the performance of the Micra VR leadless pacemaker in patients from South Korea. The primary objectives were to characterize the rate of acute (30 days) and longer-term (12 months) major complications. Electrical performance and quality of life at baseline and follow-up were also characterized.Results: A total of 100 enrolled patients underwent Micra VR implant at 8 centers in South Korea between July 2021 and February 2022 with 99% successfully implanted. Mean pacing capture threshold was 0.57±0.46 V at implant and remained stable through 12 months (0.65±0.44 V). Korean valuation of health status significantly increased from baseline (0.78±0.24) to 12 months (0.84±0.21) (p=0.016). Compared with global patients, South Korean patients were younger, had a lower body mass index, and fewer had a prior cardiovascular implantable electronic device (all p<0.01). During the follow-up period 1 major complication was reported (implant site hematoma) at 26 days post-implant. No pericardial effusion or tamponade events were observed. Through 12 months post-implant the major complication rate was 1.0% (95% confidence interval, 0.03%, 5.45%).Conclusions: In a South Korean cohort, the Micra VR leadless pacemaker was implanted with a high success rate and low major complication rate.","PeriodicalId":17850,"journal":{"name":"Korean Circulation Journal","volume":" ","pages":"526-537"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12206614/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143649113","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pathway of Leadless Pacemaker in Korea: From Now to Future. 韩国无铅起搏器之路：从现在到未来。

IF 3 3区医学

Korean Circulation Journal Pub Date : 2025-06-01 Epub Date: 2025-03-04 DOI: 10.4070/kcj.2025.0032

Ki Hong Lee

引用次数: 0

CMR Parametric Mapping Helps Diagnose Diffuse Myocardial Leukemic Infiltration in the Relapse of Acute Lymphoblastic Leukemia. CMR参数定位有助于诊断急性淋巴细胞白血病复发时弥漫性心肌白血病浸润。

IF 3 3区医学

Korean Circulation Journal Pub Date : 2025-06-01 DOI: 10.4070/kcj.2024.0334

Kyongmin Sarah Beck, Mi-Hyang Jung, Joo Hyun O, Jung Im Jung

引用次数: 0

Cryoballoon Ablation for Atrial Fibrillation in Hypertrophic Cardiomyopathy: A Step Forward or a Frozen Compromise? 冷冻球囊消融治疗肥厚性心肌病心房颤动：向前迈进一步还是冷冻妥协？

IF 3 3区医学

Korean Circulation Journal Pub Date : 2025-06-01 Epub Date: 2025-03-31 DOI: 10.4070/kcj.2025.0066

Hee Tae Yu

引用次数: 0

Cryoballoon Ablation of Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy: From the Korean Cryoballoon Ablation Registry. 肥厚性心肌病患者房颤的低温球囊消融：来自韩国低温球囊消融登记。

IF 3 3区医学

Korean Circulation Journal Pub Date : 2025-06-01 Epub Date: 2025-02-21 DOI: 10.4070/kcj.2024.0310

Myoung Jung Kim, Pil-Sung Yang, Juwon Kim, Seung-Jung Park, Kyoung-Min Park, Young Keun On, So-Ryoung Lee, Myung-Jin Cha, Chang Hee Kwon, Sung Ho Lee, Junbeom Park, Jaemin Shim, Il-Young Oh, Ki-Hun Kim, Jun-Hyung Kim, Hong Euy Lim, Ju Youn Kim

{"title":"Cryoballoon Ablation of Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy: From the Korean Cryoballoon Ablation Registry.","authors":"Myoung Jung Kim, Pil-Sung Yang, Juwon Kim, Seung-Jung Park, Kyoung-Min Park, Young Keun On, So-Ryoung Lee, Myung-Jin Cha, Chang Hee Kwon, Sung Ho Lee, Junbeom Park, Jaemin Shim, Il-Young Oh, Ki-Hun Kim, Jun-Hyung Kim, Hong Euy Lim, Ju Youn Kim","doi":"10.4070/kcj.2024.0310","DOIUrl":"10.4070/kcj.2024.0310","url":null,"abstract":"Background and objectives: Atrial fibrillation (AF) occurs in more than 20% of hypertrophic cardiomyopathy (HCM) patients, further increasing the risk of stroke. Although radiofrequency catheter ablation in AF patients with HCM has been performed, data on cryoballoon ablation (CBA) in HCM patients are limited. We evaluated the efficacy and safety of CBA in HCM patients with AF.Methods: The study included 2,649 patients with AF from the Korean CBA registry database with follow-up >12 months after de novo CBA. The primary efficacy outcome was recurrence of atrial tachyarrhythmias (ATs) ≥30s after a 3-month blanking period.Results: Totals of 1,176 paroxysmal AF (44.4%) and 1,473 persistent atrial fibrillation (PeAF, 55.6%) patients (mean age 61.7 years; 76.7% men) underwent de novo CBA. Compared to non-HCM patients (n=2,590), those with HCM (n=59) had larger left atrium and higher prevalence of heart failure, previous stroke or transient ischemic attack, and PeAF. Procedure-related complications were not statistically different between the 2 groups. During a mean follow-up period of 638±308 days, 875 (33.0%) patients experienced recurrence of ATs (845 [32.6%] non-HCM patients and 30 [50.8%] HCM patients) (p=0.01). The overall AT-free survival rate at 2 years was 45.9% in HCM group and 63.3% in non-HCM group, respectively (p=0.014), whereas there was no significant difference between the two groups in PeAF.Conclusions: CBA may be an effective rhythm control treatment for patients with AF and HCM, with an AT-free survival rate of approximately 50% at 2-year follow-up and low procedure-related complications.","PeriodicalId":17850,"journal":{"name":"Korean Circulation Journal","volume":" ","pages":"511-522"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12206609/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144000549","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Association Between Vasoactive Inotropic Score and Clinical Outcomes in Patients With Fulminant Myocarditis. 暴发性心肌炎患者血管活性性肌力评分与临床结果的关系

IF 3 3区医学

Korean Circulation Journal Pub Date : 2025-05-28 DOI: 10.4070/kcj.2024.0445

David Hong, Minjung Bak, Hyukjin Park, Hyung Yoon Kim, Seonhwa Lee, In-Cheol Kim, Junho Hyun, So Ree Kim, Mi-Na Kim, Kyung-Hee Kim, Jeong Hoon Yang

{"title":"Association Between Vasoactive Inotropic Score and Clinical Outcomes in Patients With Fulminant Myocarditis.","authors":"David Hong, Minjung Bak, Hyukjin Park, Hyung Yoon Kim, Seonhwa Lee, In-Cheol Kim, Junho Hyun, So Ree Kim, Mi-Na Kim, Kyung-Hee Kim, Jeong Hoon Yang","doi":"10.4070/kcj.2024.0445","DOIUrl":"https://doi.org/10.4070/kcj.2024.0445","url":null,"abstract":"Background and objectives: This study aimed to evaluate the prognostic value of the vasoactive inotropic score (VIS) in patients with fulminant myocarditis according to the application of venoarterial-extracorporeal membrane oxygenation (VA-ECMO).Methods: This study retrospectively analyzed 417 patients with biopsy-proven or clinically suspected fulminant myocarditis from 7 hospitals in Korea. The primary outcome was a composite of all-cause death, heart transplantation, or the use of left ventricular assist device (LVAD) at 1 year.Results: The median VIS was 19.9, and 217 (52.0%) patients received VA-ECMO. The primary outcome occurred in 105 patients (26.7%). All-cause death, heart transplantation, and the implantation of LVAD occurred in 81 (20.7%), 30 (8.7%), and 1 (0.3%) patients, respectively. VIS was associated with the risk of the primary outcome in both patients treated with VA-ECMO (hazard ratio [HR], 1.017 for every 10-point increase; 95% confidence interval [CI], 1.007-1.028; p=0.001) and patients without VA-ECMO (HR, 1.128 for every 10-point increase; 95% CI, 1.079-1.179; p<0.001), but the effect was greater in patients without who did not receive VA-ECMO (interaction p<0.001). Furthermore, the predictive performance of VIS for the primary outcome was significantly lower in patients with VA-ECMO than in those without VA-ECMO (C-index, 0.555 vs. 0.780; p value for C-index comparison, 0.002).Conclusions: In patients with fulminant myocarditis, the prognostic value of VIS was more prominent in patients without VA-ECMO than in patients with VA-ECMO. These findings suggest that the prognostic value of VIS is weakened under the influence of VA-ECMO.Trial registration: ClinicalTrials.gov Identifier: NCT05933902.","PeriodicalId":17850,"journal":{"name":"Korean Circulation Journal","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144591571","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Real-World Cost-Effectiveness of Angiotensin Receptor-Neprilysin Inhibitor in Heart Failure With Reduced Ejection Fraction in Korea. 血管紧张素受体-奈普利素抑制剂治疗韩国心力衰竭伴射血分数降低的实际成本-效果

IF 3.1 3区医学

Korean Circulation Journal Pub Date : 2025-05-27 DOI: 10.4070/kcj.2024.0403

Byeong-Chan Oh, Dong-Hyuk Cho, Jimi Choi, Sun-Hong Kwon, Byung-Su Yoo

{"title":"Real-World Cost-Effectiveness of Angiotensin Receptor-Neprilysin Inhibitor in Heart Failure With Reduced Ejection Fraction in Korea.","authors":"Byeong-Chan Oh, Dong-Hyuk Cho, Jimi Choi, Sun-Hong Kwon, Byung-Su Yoo","doi":"10.4070/kcj.2024.0403","DOIUrl":"https://doi.org/10.4070/kcj.2024.0403","url":null,"abstract":"Background and objectives: Heart failure with reduced ejection fraction (HFrEF) poses a significant burden on healthcare systems worldwide. We evaluated the real-world cost-effectiveness of angiotensin receptor-neprilysin inhibitor (ARNI) compared with traditional renin-angiotensin system (RAS) blockade in patients with HFrEF in the Korean setting.Methods: A partitioned survival model was developed based on the PARADE-HF study, which evaluated the effectiveness of ARNI in Korean HFrEF patients using National Health Insurance claims data. The model estimated medical costs, hospitalizations, life-years, and quality-adjusted life-years (QALYs) over a lifetime. Cost-effectiveness was assessed using the incremental cost-effectiveness ratio (ICER).Results: The use of ARNI resulted in additional 0.54 life-years, 0.25 QALYs gained, fewer hospitalizations (25.91 vs. 26.40) per 1,000 person-years, and an added cost of $2,880 per patient. The ICER was $11,365/QALY for all patients and $9,421/QALY for elderly patients (≥75 years). At a $20,000/QALY threshold of the willingness to pay, cost-effectiveness probabilities were 68% in all patients and 88% in elderly patients.Conclusions: In the real world, ARNI demonstrated superior cost-effectiveness compared with traditional RAS blockade in patients with HFrEF, with particularly pronounced benefits in elderly patients aged ≥75 years. The favorable cost-effectiveness profile, combined with significant reductions in mortality and hospitalization, supports the broader adoption of ARNI in clinical practice, especially for elderly patients despite concerns about tolerability in this population.","PeriodicalId":17850,"journal":{"name":"Korean Circulation Journal","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144742387","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Growth in Children with Congenital Heart Disease: Filling the Gap With Nationwide Evidence. 先天性心脏病儿童的成长：填补全国证据的空白。

IF 3 3区医学

Korean Circulation Journal Pub Date : 2025-05-27 DOI: 10.4070/kcj.2025.0139

Se Yong Jung

引用次数: 0